Clinical Trial Update: Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating intravitreally administered AIV007 in neovascular age-related macular degeneration has completed. The update notes initial safety and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• AIV007

Snippet

Sponsor: AiViva BioPharma, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1 | Status: COMPLETED